These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22643560)

  • 1. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
    Govindarajan R; Siegel E; Makhoul I; Williamson S
    Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
    Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
    J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
    Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
    Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
    Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
    Kaseb AO; Garrett-Mayer E; Morris JS; Xiao L; Lin E; Onicescu G; Hassan MM; Hassabo HM; Iwasaki M; Deaton FL; Abbruzzese JL; Thomas MB
    Oncology; 2012; 82(2):67-74. PubMed ID: 22327795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
    Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
    Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
    Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
    Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
    Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
    Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
    Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
    J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
    Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
    Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.